Table 1.
The internal medicine treatment and target for psoriasis and AD.
| Disease and Treatment | Target or Gene | Reference |
|---|---|---|
| Psoriasis | ||
| Interleukin 23-targeted therapies | ||
| Tildrakizumab | IL23 p19 | [51] |
| Guselkumab | IL23 p19 | [52] |
| Ustekinumab | p40 | [54] |
| Risankizumab | IL23 p19 | [55] |
| Interleukin 17-targeted therapies | ||
| Brodalumab | IL17 | [56] |
| Xekizumab | IL17A | [57] |
| Secukinumab | IL17A | [58] |
| Bimekizumab | IL17A, IL17F | [59] |
| Tumor necrosis factor-targeted therapies | ||
| Adalimumab | p55, p75 | [61] |
| Certolizumab | TNF-α | [62] |
| Etanercept | TNF-α | [64] |
| Atopic dermatitis | ||
| Anti-histamine | [67] | |
| Immunosuppressive drug | ||
| Cyclosporine | ||
| Methotrexate | ||
| Azathioprine | ||
| Mcophenylate mofetil | [68] | |
| Emerging therapies | ||
| Dupilumab | IL4, IL13. | [69] |
| Tralokinumab, Lebrikizumab | IL13 | [70] |
| Nemolizumab | IL31 | [71] |
| Fezakinumab | IL22 | [72] |
| Secukinumab | IL17A | [73] |
| Baricitinib | JAK1, JAK2 | [74] |
| Upadacitinib | JAK | [74] |
AD, atopic dermatitis; IL, interleukin; TNF, tumor necrosis factor; JAK, Janus kinase.